Cangene reports wider Q1 loss of $4.4M as revenue dips to US$21.5M

TORONTO – Biopharmaceutical company Cangene Corp. (TSX:CNJ) has reported an increase in its first-quarter net loss, citing an absence of royalty revenues and increased research costs.